On the commercial front, Akeso's adjustments in drug pricing and optimization of its commercial systems led to new drug sales revenue surpassing RMB 2 billion in 2024, a 25% year-on-year increase. The ...

During the last three months, 5 analysts shared their evaluations of Y-mAbs Therapeutics (NASDAQ:YMAB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Antonio Abreu (Portugal) was appointed Director of the Division of Ecological and Earth Sciences in the Natural Sciences Sector of UNESCO and Secretary of the MAB Programme in April 2023.

Y MABS THERAPEUTICS ($YMAB) is expected to release its quarterly earnings data on Tuesday, March 4th before market open, per Finnhub. Analysts are expecting revenue ...

Our lead programs target the PCSK9 and ANGPTL3 genes, which have been extensively validated as targets for lowering LDL cholesterol, or LDL-C. We believe that editing these genes could potently ...

PUTRAJAYA: Malaysia Airlines Bhd (MAB) must ensure its subsidiary, MAB Engineering Services, takes decisive measures to attract skilled new workers. Transport Minister Anthony Loke said efforts ...